Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Debt (2020 - 2024)

Syndax Pharmaceuticals has reported Total Debt over the past 5 years, most recently at $343.7 million for Q4 2024.

  • Quarterly results put Total Debt at $343.7 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $343.7 million (changed N/A YoY), and the annual figure for FY2024 was $343.7 million, changed.
  • Total Debt for Q4 2024 was $343.7 million at Syndax Pharmaceuticals, up from $20.2 million in the prior quarter.
  • Over the last five years, Total Debt for SNDX hit a ceiling of $343.7 million in Q4 2024 and a floor of $19.8 million in Q1 2020.
  • Median Total Debt over the past 4 years was $20.1 million (2020), compared with a mean of $49.5 million.
  • Biggest five-year swings in Total Debt: increased 2.36% in 2021 and later decreased 0.92% in 2022.
  • Syndax Pharmaceuticals' Total Debt stood at $20.1 million in 2020, then fell by 0.18% to $20.1 million in 2021, then increased by 0.62% to $20.2 million in 2022, then soared by 1600.89% to $343.7 million in 2024.
  • The last three reported values for Total Debt were $343.7 million (Q4 2024), $20.2 million (Q2 2022), and $20.0 million (Q1 2022) per Business Quant data.